Sarepta reports $1.86 billion in 2025 product revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
January 12, 2026 11:58 AM ESTPreliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025 Preliminary PMO net product revenues totaled $259.2 million for the fourth quarter and $965.6 million for full-year 2025 Preliminary year-end 2025 cash, cash equivalents, restricted cash and investments balance of approximately $953.8 million
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare... More
